Decoy Therapeutics Inc.
No SEC Form 4 filings for $DCOY in the last 30 days.
See all $DCOY insider activity →Decoy Therapeutics Inc. (DCOY) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 14, 2026, Decoy Therapeutics Inc. (the “Company”) convened a Special Meeting of Stockholders (the “Special Meeting”). As of July 20, 2026, the record date for the Special Meeting, there were 590,185 shar
Opus Genetics (IRD) rose 27% after positive clinical trial data. Quantum (QNTM) gained 10% with FDA Phase 2 trial clearance. Pulse Biosciences (PLSE) surged 15% without specific news. Decoy Therapeutics (DCOY) and ONWARD Medical (ONWD.BR) also traded higher on updates.
Decoy Therapeutics (NASDAQ:DCOY) said its IP portfolio grew to seven patent families and 19 pending applications in seven jurisdictions, including one granted U.S. patent. The filings cover antiviral peptide conjugates, peptide synthesis and linker methods, and compounds targeting conserved viral fusion protein features, including measles and Nipah. The company also filed a June 2026 application tied to its IMPACT platform.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning DCOY (Decoy Therapeutics Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent DCOY coverage spans corporate actions, technology and market movers.
Potential dilution from warrant conversion and a slight reduction in authorized share count.
Conference appearance may raise visibility but lacks substantive news.
New patent filings strengthen Decoy’s defensibility around its antiviral peptide conjugates and IMPACT platform, but they are not clinical or regulatory milestones.
This is a routine corporate governance 8-K with no new operating or financial guidance, so near-term price impact is likely limited.
A sizable PIPE with warrant overhang is a capital-structure catalyst that can pressure shares even as it funds programs.
AlphAI scores every news story that mentions DCOY with an AI model for sentiment and relevance, and aggregates insider trades from Decoy Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Decoy Therapeutics Inc. (DCOY) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 14, 2026, Decoy Therapeutics Inc. (the “Company”) convened a Special Meeting of Stockholders (the “Special Meeting”). As of July 20, 2026, the record date for the Special Meeting, there were 590,185 shar
1 min readOpus Genetics (IRD) rose 27% after positive clinical trial data. Quantum (QNTM) gained 10% with FDA Phase 2 trial clearance. Pulse Biosciences (PLSE) surged 15% without specific news. Decoy Therapeutics (DCOY) and ONWARD Medical (ONWD.BR) also traded higher on updates.
3 min readDecoy Therapeutics (NASDAQ:DCOY) said its IP portfolio grew to seven patent families and 19 pending applications in seven jurisdictions, including one granted U.S. patent. The filings cover antiviral peptide conjugates, peptide synthesis and linker methods, and compounds targeting conserved viral fusion protein features, including measles and Nipah. The company also filed a June 2026 application tied to its IMPACT platform.
2 min readDecoy Therapeutics Inc. (DCOY) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001615219 false 0001615219 2026-07-14 2026-07-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14,
1 min readBiotech gainers highlighted: Universe Pharma (UPC) surged 311% after agreeing to buy Best Praise International for $10.75M in shares to expand its China patent portfolio; Decoy Therapeutics (DCOY) rose 74% on a PIPE up to $21M; QuidelOrtho (QDEL) gained 32% on reports it may sell its point-of-care unit for about $1.5B; SELLAS (SLS) jumped 25% ahead of AML trial readouts.
6 min readDecoy Therapeutics Inc. (DCOY) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 7 dcoy-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 26, 2026, between Decoy Therapeutics Inc., a Delaware corporation (the “ Company ”), and each of the purchasers identif
6 min read